The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
A Phase III trial of AstraZeneca PLC’s Calquence has met its primary endpoint, marking the second time in as many months that the drug has passed a pivotal test.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
